Medical treatment of idiopathic intracranial hypertension is often ineffective. Cerebrospinal fluid diversion or optic nerve sheath fenestration is employed when medical therapy fails. Here, we describe a case of a 13-year-old girl with idiopathic intracranial hypertension refractory to long-term trials of acetazolamide and furosemide at maximally tolerated doses. After declining surgical intervention despite progression of her visual symptoms, a trial of bumetanide (0.25 mg daily) monotherapy was successful in resolution of the patient’s symptoms. These results suggest bumetanide could be effective in the treatment of idiopathic intracranial hypertension, perhaps by restoring the balance between cerebrospinal fluid formation and absorption and/or by altering the volume or ionic composition of the brain’s extracellular fluid compartment.
Johnson L.The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). Ophthalmology. 1998;105(12):2313-2317.
3.
Schoeman JFChildhood pseudotumor cerebri: clinical and intracranial pressure response to acetazolamide and furosemide treatment in a case series. J Child Neurol. 1994;9(2):130-134.
4.
Eggenberger ER, Miller NR, Vitale S.Lumboperitoneal shunt for the treatment of pseudotumor cerebri. Neurology. 1996;46(6): 1524-1530.
5.
Spoor TC, Ramocki JM, Madion MP, Wilkinson MJTreatment of pseudotumor cerebri by primary and secondary optic nerve sheath decompression. Am J Ophthalmol. 1991;112(2):177-185.
6.
Mirza N., Marson AG, Pirmohamed M.Effect of topiramate on acid-base balance: extent, mechanism and effects. Br J Clin Pharmacol.2009;68(5):655-661.
7.
Hannaert P., Alvarez-Guerra M., Pirot D., Nazaret C., Garay RPRat NKCC2/NKCC1 cotransporter selectivity for loop diuretic drugs. Naunyn Schmiedebergs Arch Pharmacol. 2002;365(3):193-199.
8.
Donaldson JOPathogenesis of pseudotumor cerebri syndromes . Neurology. 1981;31(7):877-880.
9.
Walker RWIdiopathic intracranial hypertension: any light on the mechanism of the raised pressure? J Neurol Neurosurg Psychiatr. 2001 ;71(1):1-5.
10.
Gjerris F., Soelberg Sørensen P., Vorstrup S., Paulson OBIntracranial pressure, conductance to cerebrospinal fluid outflow, and cerebral blood flow in patients with benign intracranial hypertension (pseudotumor cerebri). Ann Neurol. 1985;17(2):158-162.
11.
Raichle ME, Grubb RL, Phelps ME, Gado MH, Caronna JJCerebral hemodynamics and metabolism in pseudotumor cerebri. Ann Neurol. 1978;4(2):104-111.
12.
Johnston I.Reduced C.S.F.absorption syndrome: reappraisal of benign intracranial hypertension and related conditions. Lancet. 1973;2(7826):418-421.
13.
Sklar FH, Beyer CW, Ramanathan M., Cooper PR, Clark WKCerebrospinal fluid dynamics in patients with pseudotumor cerebri. Neurosurgery. 1979;5(2):208-216.
14.
Janny P., Chazal J., Colnet G., Irthum B., Georget AMBenign intracranial hypertension and disorders of CSF absorption. Surg Neurol. 1981;15(3):168-174.
15.
Orefice G., Celentano L., Scaglione M., Davoli M., Striano S.Radioisotopic cisternography in benign intracranial hypertension of young obese women: a seven-case study and pathogenetic suggestions. Acta Neurol (Napoli)1992;14(1):39-50.
16.
Guess HA, Charlton JD, Johnson RN, Mann JDA nonlinear least-squares method for determining cerebrospinal fluid formation and absorption kinetics in pseudotumor cerebri. Comput Biomed Res. 1985;18(2):184-192.
17.
Sørensen PS, Thomsen C., Gjerris F., Henriksen O.Brain water accumulation in pseudotumour cerebri demonstrated by MRimaging of brain water self-diffusion. Acta Neurochir Suppl (Wien). 1990;51:363-365.
18.
Bastin ME, Sinha S., Farrall AJ, Wardlaw JM, Whittle IRDiffuse brain oedema in idiopathic intracranial hypertension: a quantitative magnetic resonance imaging study. J Neurol Neurosurg Psychiatr . 2003;74(12):1693-1696.
19.
Liu GT, Volpe NJ, Galetta SLPseudotumor cerebri and its medical treatment. Drugs Today . 1998;34(6):563-574.
Gücer G., Viernstein L.Long-term intracranial pressure recording in the management of pseudotumor cerebri. J Neurosurg. 1978; 49(2):256-263.
22.
Rubin RC, Henderson ES, Ommaya AK, Walker MD, Rall DPThe production of cerebrospinal fluid in man and its modification by acetazolamide . J Neurosurg. 1966;25(4):430-436.
23.
Thenuwara K. , Todd MM, Brian JEEffect of mannitol and furosemide on plasma osmolality and brain water. Anesthesiology. 2002;96(2):416-421.
24.
Greene CS, Lorenzo AV, Hornig G., Welch K.The lowering of cerebral spinal fluid and brain interstitial pressure of preterm and term rabbits by furosemide. Z Kinderchir. 1985;40Suppl1:5-8.
25.
Artru AA, Powers KMFurosemide decreases cerebrospinal fluid formation during desflurane anesthesia in rabbits. J Neurosurg Anesthesiol. 1997;9(2):166-174.
26.
McCarthy KD , Reed DJThe effect of acetazolamide and furosemide on cerebrospinal fluid production and choroid plexus carbonic anhydrase activity . J Pharmacol Exp Ther. 1974; 189(1):194-201.
27.
Simon DB, Karet FE, Hamdan JM, et al. Bartter’s syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat Genet. 1996; 13(2):183-188.
28.
Curry WT, Butler WE, Barker FGRapidly rising incidence of cerebrospinal fluid shunting procedures for idiopathic intracranial hypertension in the United States, 1988-2002. Neurosurgery. 2005;57(1):97-108.
McGirt MJ, Woodworth G., Thomas G., et al. Cerebrospinal fluid shunt placement for pseudotumor cerebri-associated intractable headache: predictors of treatment response and an analysis of long-term outcomes. J Neurosurg . 2004;101(4):627-632.
31.
Plotkin MD, Snyder EY, Hebert SC, Delpire E.Expression of the Na-K-2Cl cotransporter is developmentally regulated in postnatal rat brains: a possible mechanism underlying GABA’s excitatory role in immature brain. J Neurobiol. 1997;33(6):781-795.
32.
Kahle KT, Simard JM, Staley KJ, et al. Molecular mechanisms of ischemic cerebral edema: role of electroneutral ion transport. Physiology (Bethesda). 2009;24:257-265.
33.
Payne JA, Rivera C., Voipio J., Kaila K.Cation-chloride co-transporters in neuronal communication, development and trauma. Trends Neurosci. 2003;26(4):199-206.
34.
Brandt C., Nozadze M., Heuchert N., Rattka M., Löscher W.Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy. J Neurosci.2010;30(25):8602-8612.
35.
Nardou R., Ben-Ari Y., Khalilov I.Bumetanide, an NKCC1 antagonist, does not prevent formation of epileptogenic focus but blocks epileptic focus seizures in immature rat hippocampus. J Neurophysiol. 2009;101(6):2878-2888.
36.
Kahle KT, Barnett SM, Sassower KC, Staley KJDecreased seizure activity in a human neonate treated with bumetanide, an inhibitor of the Na(+)-K(+)-2Cl(-) cotransporter NKCC1. J Child Neurol.2009;24(5):572-576.
37.
Keep RF, Xiang J., Betz ALPotassium cotransport at the rat choroid plexus. Am J Physiol . 1994;267(6Pt1):C1616-C1622.
38.
Bairamian D. , Johanson CE, Parmelee JT, Epstein MHPotassium cotransport with sodium and chloride in the choroid plexus. J Neurochem. 1991;56(5):1623-1629.
39.
Johanson CE , Sweeney SM, Parmelee JT, Epstein MHCotransport of sodium and chloride by the adult mammalian choroid plexus. Am J Physiol Cell Physiol . 1990;258(2):C211-C216.
40.
Javaheri S. , Wagner KRBumetanide decreases canine cerebrospinal fluid production: in vivo evidence for NaCl cotransport in the central nervous system. J Clin Invest. 1993;92(5): 2257-2261.
